Nicholas Landekic has had one of the most successful and respected careers of any healthcare executive, with 25 years of experience with both major pharmaceutical as well as biotechnology companies, and has done some of the largest and most important financing and corporate licensing deals in the healthcare industry. Prior to founding PolyMedix in 2002, from 2000-2002, he was President & C.E.O. and the first employee of Locus Pharmaceuticals, where in two years he raised $83 million in venture financings, hired over 50 employees, started 12 drug discovery programs, built one of the most powerful supercomputers in the world, and earned for the company the accolade "One of the 10 hottest biotech start-ups" from Drug Discovery Today magazine. Prior to Locus, from 1995-2000 he was Sr. Vice President Corporate Development & Investor Relations at Guilford Pharmaceuticals, where he concluded a $465 million deal with Amgen and a $100 million deal with Rhone-Poulenc Rorer. His deals have twice been nominated for "Allicense Deal of the Year". Prior to Guilford, from 1991-1995 he was Sr. Director, Business Development at Cephalon; from 1988-1991 Sr. Manager, Strategic Marketing at Bristol-Myers Squibb; from 1985-1988 positions in Finance and Business Development at Johnson & Johnson Corporation (McNeil Pharmaceutical); and has also worked in the research laboratories at the Mt. Sinai Medical Center from 1982-1983. He holds an M.B.A. from the State University of New York at Albany, an M.S. Biology from Indiana University, and a B.S. Biology from Marist College.

Frank Slattery, Jr. has served as Chairman of the Board of Directors of PolyMedix, Inc. since November 2005 and was a co-founder of PolyMedix Pharmaceuticals, Inc. where he served in the same capacity since inception in August 2002. Frank Slattery was the President, Chief Executive Officer and Director of LFC Financial Corp. from 1969 to 1994. Mr. Slattery has founded and currently serves as the Chairman of the Board of Directors of several privately held companies, including Main Line Health Systems, Inc., GelMed Inc., Probaris Technologies, Inc., Franklin Fuel Cells, Inc., Knite, Inc., Learned Optimism, Inc. and NanoSelect, Inc. He also currently serves as a director of Clarient, Inc., a publicly held company, and as a Trustee of the Jefferson Health System. Mr. Slattery holds an A.B. from Princeton University and a J.D. from the Law School of the University of Pennsylvania.

William N. Kelley, M.D. has served as a Director of PolyMedix, Inc. since November 2005 and of PolyMedix Pharmaceuticals, Inc. since August 2005. Dr. Kelley has served as Professor of Medicine and Professor of Biochemistry and Biophysics at the School of Medicine of the University of Pennsylvania since 1989. From 1989 to 2000, Dr. Kelley served as Executive Vice President of the University of Pennsylvania with responsibilities as Chief Executive Officer for the Medical Center (and Health Systems upon its formation in 1993), Dean of the School of Medicine, and the Robert G. Dunlop Professor of Medicine and Biochemistry and Biophysics. From 1975 to 1989, Dr. Kelley was the John G. Searle Professor and Chair of the Department of Internal Medicine and Professor of Biological Chemistry at the University of Michigan. Prior to joining the faculty at the University of Michigan, Dr. Kelley was Professor of Medicine at Duke University Medical Center. Dr. Kelley currently serves as a director of Merck & Co., Beckman Coulter, Inc. and GenVec, Inc., which are all publicly held companies, and Advanced Bio-Surfaces, Inc., a privately held company. During his career, Dr. Kelley has also served on the editorial boards of 13 medical journals and his bibliography includes over 260 publications, including 17 books. Dr. Kelley holds an M.D. from Emory University.

Michael E. Lewis, Ph.D. has served as a Director of PolyMedix, Inc. since November 2005 and of PolyMedix Pharmaceuticals, Inc. since its inception. Dr. Lewis has more than 30 years of scientific experience in academic and government laboratories and in several major pharmaceutical and biotechnology companies. Since 1994, Dr. Lewis has served as President of BioDiligence Partners, Inc., where he co-founded three other biotechnology companies, Cara Therapeutics, Inc., Arena Pharmaceuticals, Inc. and Adolor Corporation. Dr. Lewis has served as Chief Scientific Advisor and a director of Cara Therapeutics, Inc. since its inception in 2004. He has also served as a director of Aeolus Pharmaceuticals, Inc. since 2004. After serving as Chief Scientific Advisor of Adolor Corporation from 1994 to 1997, Dr. Lewis served as Chief Scientific Advisor of Arena Pharmaceuticals, Inc. from 1997 to 2003, and as a director from 1997 to 2000. Dr. Lewis is a co-founder of Cephalon, Inc. and served as Senior Scientist, Director of Pharmacology, and then as Senior Director of Scientific Affairs from 1988 to 1993. He supervised a molecular pharmacology research laboratory at the E.I. DuPont Co. from 1985 to 1987, and received postdoctoral training in pharmacology at the National Institutes of Health, the University of Michigan, and at the University of Cambridge. He received a Ph.D. from Clark University in 1977.

Shaun F. O’Malley has served as a Director of PolyMedix, Inc. since January 2006. Mr. O’Malley is currently the Chairman Emeritus of Price Waterhouse LLP, a title he has held since July 1995. Prior to 1995, he served as Chairman and Senior Partner of Price Waterhouse LLP. He currently serves as a member of the Boards of Directors of the Finance Company of Pennsylvania, Philadelphia Consolidated Holdings, Inc., Federal Home Loan Mortgage Corporation, the Horace Mann Educators Corporation and The Philadelphia Contributionship. Mr. O’Malley is also a member of the Board of Trustees of the University of Pennsylvania Health System. Mr. O’Malley holds a B.S. in Economics from the Wharton School of the University of Pennsylvania.

Brian Anderson brings over thirty years of experience in the pharmaceutical and biotechnology industries to PolyMedix. Educated at the University of Manitoba, Brian commenced his career in the pharmaceutical industry at Pharmacia (later Pharmacia & Upjohn), where he spent fifteen years in progressively senior positions in sales and marketing. He then served for eight years at Bristol-Myers Squibb in executive positions in business development and marketing. During the past ten years Brian has served in senior positions with several development-stage biotechnology companies, as the Senior Vice President of Corporate Development at Interneuron (now Indevus), Chief Business Officer of MediciNova, and President & C.E.O. of Cognetix. He has served on the Board of Directors of Oragenics and Omni-Genetics.

return to top ^